Key Points
- Ivan Hyep, Bicara Therapeutics' CFO, sold 9,200 shares on April 21 at an average price of $23.00 for $211,600, a transaction executed under a pre‑arranged Rule 10b5‑1 plan that trimmed his stake to 145,355 shares (down 5.95%).
- Including earlier sales in March and January, Hyep has sold a total of 36,800 shares since January, generating approximately $717,189 in proceeds across those transactions.
- Shares of NASDAQ:BCAX trade near recent highs (opened $23.63; 52‑week high $24.25) with a market cap of about $1.55B and a consensus analyst view of "Moderate Buy" (average target ~$28, individual targets up to $42).
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the business's stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $23.00, for a total transaction of $211,600.00. Following the completion of the sale, the chief financial officer owned 145,355 shares of the company's stock, valued at approximately $3,343,165. This represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ivan Hyep also recently made the following trade(s):
- On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total transaction of $170,384.00.
- On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75.
- On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total transaction of $246,972.10.
- On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30.
Bicara Therapeutics Stock Up 2.3%
Shares of NASDAQ:BCAX opened at $23.63 on Thursday. The firm has a 50 day moving average of $19.16 and a 200 day moving average of $17.72. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.34 and a beta of -1.23. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $24.25.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.04. On average, sell-side analysts expect that Bicara Therapeutics Inc. will post -2.72 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on BCAX. Wedbush restated an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Wells Fargo & Company increased their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 31st. Citizens Jmp restated a "market outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, HC Wainwright lifted their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.00.
View Our Latest Research Report on Bicara Therapeutics
Institutional Investors Weigh In On Bicara Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $45,000. Legal & General Group Plc raised its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock valued at $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock worth $97,000 after purchasing an additional 4,585 shares in the last quarter.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
